Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement

被引:71
|
作者
Schiffmann, R
Rapkiewicz, A
Abu-Asab, M
Ries, M
Askari, H
Tsokos, M
Quezado, M
机构
[1] NINDS, Dev & Metab Neurol Branch, NIH, Bethesda, MD 20892 USA
[2] NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA
关键词
Fabry disease; lysosomes; atherosclerosis; myocardial infarction; enzyme replacement therapy; glycolipids;
D O I
10.1007/s00428-005-0089-x
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
We describe the postmortem findings of a 47-year-old man with Fabry disease, an X-linked glycolipid storage disorder, who was on enzyme replacement therapy with recombinant alpha-galactosidase A for more than 2 years. The patient had widespread atherosclerotic coronary artery disease that culminated in a massive acute myocardial infarction. Atherosclerotic lesions were seen in the right and left coronary systems, aorta, and the basilar artery. Typical Fabry cardiomyopathy and glomerular nephropathy were found. With the exception of vascular endothelial cells, extensive glycolipid storage deposits were seen in all vascular and nonvascular cells and organ systems. We conclude that, at least in this patient, repeated infusions with alpha-galactosidase A over a prolonged period did not appreciably clear storage material in cells other than vascular endothelial cells. These findings also illustrate accelerated atherosclerosis in susceptible patients with Fabry disease.
引用
收藏
页码:337 / 343
页数:7
相关论文
共 50 条
  • [41] Enzyme replacement therapy improves cardiac features and severity of Fabry disease
    Motwani, Manish
    Banypersad, Sanjay
    Woolfson, Peter
    Waldek, Stephen
    MOLECULAR GENETICS AND METABOLISM, 2012, 107 (1-2) : 197 - 202
  • [42] Enzyme replacement therapy and renal function in 201 patients with Fabry disease
    Schwarting, A.
    Dehout, F.
    Feriozzi, S.
    Beck, M.
    Mehta, A.
    Sunder-Plassmann, G.
    CLINICAL NEPHROLOGY, 2006, 66 (02) : 77 - 84
  • [43] Clinical features and enzyme replacement therapy in 10 children with Fabry disease
    Li, Qian
    Wang, Jing
    Tian, Minle
    Yang, Zhenle
    Yu, Lichun
    Liu, Suwen
    Wang, Cong
    Wang, Xiaoyuan
    Sun, Shuzhen
    FRONTIERS IN PEDIATRICS, 2023, 11
  • [44] Neuropathic pain in Fabry's disease:: Heterogeneous remission in three years of enzyme replacement therapy
    Dominguez, R. O.
    Amartino, H.
    Chamoles, N. A.
    REVISTA DE NEUROLOGIA, 2006, 43 (04) : 201 - 206
  • [45] Fabry disease: recent advances in enzyme replacement therapy
    Germain, DP
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2002, 11 (10) : 1467 - 1476
  • [46] Neuropathy and Fabry disease: pathogenesis and enzyme replacement therapy
    Schiffmann, Raphael
    ACTA NEUROLOGICA BELGICA, 2006, 106 (02) : 61 - 65
  • [47] Fabry disease: a review of current enzyme replacement strategies
    Mehta, Atul
    EXPERT OPINION ON ORPHAN DRUGS, 2015, 3 (11): : 1319 - 1330
  • [48] Enzyme replacement therapy in Fabry disease: clinical implications
    Breunig, F
    Knoll, A
    Wanner, C
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2003, 12 (05) : 491 - 495
  • [49] Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement
    Moore, DF
    Altarescu, G
    Ling, GSF
    Jeffries, N
    Frei, KP
    Weibel, T
    Charria-Ortiz, G
    Ferri, R
    Arai, AE
    Brady, RO
    Schiffmann, R
    STROKE, 2002, 33 (02) : 525 - 531
  • [50] Enzyme replacement therapy in patients with Fabry's disease
    Tsuboi, K.
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2007, 35 (04) : 574 - 581